Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunhild von Amsberg

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Der Urologe. Ausg. A|April 3, 2020
[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial]Gunhild von Amsberg
Urologie (Heidelberg, Germany)|November 12, 2025
[Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons]Gunhild von Amsberg
Urologie (Heidelberg, Germany)|November 13, 2023
[Metastatic castration-resistant prostate cancer-emerging trends in therapy]Gunhild von Amsberg, Tilman Todenhöfer
Deutsche Medizinische Wochenschrift (1946)|June 24, 2017
[New Aspects in Treatment of Metastatic Prostate Cancer]Gunhild von Amsberg, Carsten Bokemeyer
Aktuelle Urologie|March 27, 2024
[Molecular testing of prostate cancer: timing, methods and consequences]Gunhild von Amsberg, Finn-Ole Paulsen
Oncology Research and Treatment|May 20, 2020
[Vorwort]Gunhild von Amsberg, Jürgen Erich Gschwend
Urologie (Heidelberg, Germany)|February 10, 2025
[Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]Gunhild von Amsberg, Sergey Dyshlovoy, Moritz Kaune
Der Urologe. Ausg. A|July 2, 2021
[Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update]Gunhild von Amsberg, Holger Thiele, Axel Merseburger
Urologie (Heidelberg, Germany)|September 5, 2024
[Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors]Jozefina Casuscelli, Gunhild von Amsberg, Margitta Retz
Oncology Research and Treatment|May 16, 2018
Clinical Stage IIA-IIC Seminoma: Radiation Therapy versus Systemic Chemotherapy versus Retroperitoneal Lymph Node DissectionGunhild von Amsberg, Robert Hamilton, Alexandros Papachristofilou
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Der Urologe. Ausg. A|April 3, 2020
[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial]Gunhild von Amsberg
Urologie (Heidelberg, Germany)|November 12, 2025
[Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons]Gunhild von Amsberg
Urologie (Heidelberg, Germany)|November 13, 2023
[Metastatic castration-resistant prostate cancer-emerging trends in therapy]Gunhild von Amsberg, Tilman Todenhöfer
Deutsche Medizinische Wochenschrift (1946)|June 24, 2017
[New Aspects in Treatment of Metastatic Prostate Cancer]Gunhild von Amsberg, Carsten Bokemeyer
Aktuelle Urologie|March 27, 2024
[Molecular testing of prostate cancer: timing, methods and consequences]Gunhild von Amsberg, Finn-Ole Paulsen
Oncology Research and Treatment|May 20, 2020
[Vorwort]Gunhild von Amsberg, Jürgen Erich Gschwend
Urologie (Heidelberg, Germany)|February 10, 2025
[Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]Gunhild von Amsberg, Sergey Dyshlovoy, Moritz Kaune
Der Urologe. Ausg. A|July 2, 2021
[Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update]Gunhild von Amsberg, Holger Thiele, Axel Merseburger
Urologie (Heidelberg, Germany)|September 5, 2024
[Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors]Jozefina Casuscelli, Gunhild von Amsberg, Margitta Retz
Oncology Research and Treatment|May 16, 2018
Clinical Stage IIA-IIC Seminoma: Radiation Therapy versus Systemic Chemotherapy versus Retroperitoneal Lymph Node DissectionGunhild von Amsberg, Robert Hamilton, Alexandros Papachristofilou
Pageof 13